GSK plc's RSV vaccine Arexvy has been accepted for regulatory review in China for adults aged 60+, with an expected decision in 2027. This vaccine could help over six million impacted by RSV in China each year.
AI Assistant
GSK PLC
2026
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.